XML 24 R10.htm IDEA: XBRL DOCUMENT v3.25.3

Composition of Certain Consolidated Financial Statement Line Items

9 Months Ended

Sep. 30, 2025

Composition of Certain Consolidated Financial Statement Line Items

Composition of Certain Consolidated Financial Statement Line Items

3. Composition of Certain Consolidated Financial Statement Line Items

Accrued expenses and other current liabilities consisted of the following (in thousands):

​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​
​	​	SEPTEMBER 30,		​	DECEMBER 31,		​
​		2025			2024
Accrued compensation	​	$	8,551	​	$	7,290	​
Accrued research and development expenses	​		5,192	​		5,460	​
Accrued clinical expenses	​	​	13,493	​	​	7,025	​
Accrued professional services	​	​	3,122	​	​	2,918	​
Accrued other liabilities	​		6,571	​		3,606	​
Total accrued expenses and other current liabilities	​	$	36,929	​	$	26,299	​
​	​	​	​	​	​	​	​

​

X

- References

No definition available.

+ Details

Name:	srt_ItemsIncludedInConsolidatedStatementOfFinancialConditionAbstract
Namespace Prefix:	srt_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/210/tableOfContent

+ Details

Name:	us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration